Folate pathway enzyme (primarily Dihydrofolate reductase and related enzymes)

The "Folate pathway modulation via tetrahydrofolate analog activity" refers to the therapeutic targeting of key enzymes within the folic acid metabolic cycle—most notably dihydrofolate reductase—using drugs that mimic or inhibit natural folates. Tetrahydrofolic acid is the active form derived from dietary folic acid and serves as an essential coenzyme for one-carbon transfer reactions required for purine/thymidylate nucleotide biosynthesis, amino acid interconversion, and methylation processes critical to cell division and epigenetic regulation. Inhibitors such as methotrexate, trimethoprim, pyrimethamine, sulfonamides, raltitrexed, and others exploit differences between human/microbial/parasite pathways to selectively disrupt nucleic acid synthesis in cancerous tissues or infectious agents. These drugs are widely used across oncology (chemotherapy), infectious diseases (antibacterials/antiparasitics), autoimmune disorders, but their use can be limited by toxicity to normal proliferating tissues and by acquired resistance mechanisms involving altered drug transport/metabolism/polyglutamation.

Other names

Folate metabolism enzymesTetrahydrofolate pathway enzymesDHFR (Dihydrofolate reductase) and related folate cycle targets

Inhibition of dihydrofolate reductase to block tetrahydrofolate production, halting DNA/RNA synthesis in rapidly dividing cells or pathogens.